Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bioxcel Therapeutics ( (BTAI) ) has issued an announcement.
On August 1, 2025, BioXcel Therapeutics announced the completion of patient visits in its SERENITY At-Home Pivotal Phase 3 Safety Trial for BXCL501, targeting agitation in bipolar and schizophrenia patients. The trial involved over 200 participants across 22 sites, with data from more than 2,200 agitation episodes collected, and results expected soon, potentially impacting the company’s market position and stakeholder interests.
The most recent analyst rating on (BTAI) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.
Spark’s Take on BTAI Stock
According to Spark, TipRanks’ AI Analyst, BTAI is a Underperform.
Bioxcel Therapeutics’ stock is rated at the lowest end of the scale due to substantial financial instability, including ongoing losses, high debt, and negative cash flows. Short-term technical indicators and valuation metrics further highlight the current challenges. The company needs to address these financial and operational issues to improve its stock performance.
To see Spark’s full report on BTAI stock, click here.
More about Bioxcel Therapeutics
BioXcel Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing innovative medicines for the treatment of neuropsychiatric and rare diseases. Their primary product, BXCL501, is aimed at treating agitation associated with neuropsychiatric disorders such as bipolar disorders and schizophrenia.
Average Trading Volume: 343,844
Technical Sentiment Signal: Sell
Current Market Cap: $7.93M
See more data about BTAI stock on TipRanks’ Stock Analysis page.